Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BYM338 in COPD-associated cachexia
NL-OMON39660Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) and cachexia comparing BYM338 with Placebo (2 arms). Primary endpoint: Thigh muscle volume. Started Jun 2013; status: active, not recruiting.
02
Drugs
bimagrumab
03
Conditions
chronic obstructive pulmonary disease (COPD)cachexia
Beyond the preview
Go deeper on NL-OMON39660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39660.